ReviewCurrent oncology reports2013
Dermatological adverse events from BRAF inhibitors: a growing problem.
Review in Current oncology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2017Pooled it
- ERK hyperactivation in epidermal keratinocytes impairs intercellular adhesion and drives Grover disease pathology.JCI insight · 2024Article
- Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.Cancer discovery · 2021Article
- Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.Investigational new drugs · 2021Article
- Many Distinct Ways Lead to Drug Resistance inLife (Basel, Switzerland) · 2021Review
- Adverse Event Management in Patients withThe oncologist · 2019Article
- Uncommon Presentation of Metastatic Squamous Cell Carcinoma of the Skin and Treatment Challenges.The American journal of case reports · 2019Article
- Pruritus Associated with Targeted Anticancer Therapies and Their Management.Dermatologic clinics · 2018Review
- Early phase clinical trials to identify optimal dosing and safety.Molecular oncology · 2015Review
- Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.Cancer biology & therapy · 2014Article
- Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma.Journal of the advanced practitioner in oncology · 2014Review
- Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2014Review
- Cutaneous side effects of vemurafenib: a case report and discussion.Wiener medizinische Wochenschrift (1946) · 2013Article
- Unusual and Interesting Adverse Cutaneous Drug Reactions.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of targeted therapies has ushered in a new era in the management of melanoma. Inhibitors of the RAS-RAF-MEK-ERK pathway have taken the center stage with development at a rapid pace. Vemurafenib was recently approved by regulatory agencies, and other agents (e.g. dabrafenib) are in various stages of clinical testing. These agents are producing remarkable results for patients, but are also presenting new challenges. Clinical toxicities and drug resistance are topmost issues. Some of the most common and vivid representations of adverse events to these agents are the dermatologic manifestations. Published trials and initial observations reflect a toxicity profile (e.g. squamous cell carcinomas/keratoacanthomas, maculopapular rashes, hyperkeratosis) that is distinct from cutaneous toxicities from EGFR and mTOR inhibitors (acneiform rash, paronychia, xerosis). Their management extends beyond conservative treatment and includes specific physical and surgical treatment modalities, skill sets unique to dermatologists. All these pose significant challenges to clinicians, and sound knowledge of such toxicities and their management will likely result in improved patient outcomes and quality of life. In this manuscript, we provide an overview of the emerging scientific literature on dermatological adverse events arising out of BRAF inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.